ACT Genomics provides genomic profiling services that deliver actionable insights on biomarkers and genomic alterations to tailor cancer treatment plans for patients. By utilizing precision testing, the company enhances treatment selection and clinical trial matching, improving patient outcomes in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment is often hindered by a lack of precise information about the unique genomic characteristics of a patient's tumor, leading to suboptimal treatment selection and limited clinical trial options. This can result in reduced effectiveness of therapies and poorer patient outcomes.
Solution
ACT Genomics offers comprehensive genomic profiling services that analyze a patient's tumor at the molecular level, providing actionable insights for personalized cancer care. By identifying specific biomarkers and genomic alterations, the company enables clinicians to tailor treatment plans, match patients with relevant clinical trials, and monitor disease progression. Their next-generation sequencing (NGS) platform, coupled with bioinformatics analysis and curated databases, delivers reliable results for both clinical and research purposes. ACT Genomics aims to transform cancer management by providing ongoing support to doctors and patients, ensuring optimal guidance and resources for the most effective treatment strategies.
Target Audience
The primary target audience includes oncologists, physicians, and biopharmaceutical companies seeking to improve cancer care through personalized treatment strategies and biomarker discovery.
Features
- Comprehensive genomic profiling across all solid cancers using next-generation sequencing (NGS)
- Identification of biomarkers and genomic alterations to guide treatment decisions
- Clinical trial matching based on individual tumor profiles
- Monitoring of disease progression and treatment response
- Bioinformatics analysis and curated proprietary databases for reliable results
- Data visualization technologies for easy understanding of scientific results
- Services for cancer prevention, early detection, and risk assessment
- Expertise in Homologous Recombination Deficiency (HRD) testing for ovarian cancer